Chutima Kunacheewa, Pei Lin, Elisabet E. Manasanch
{"title":"多发性骨髓瘤极小残留病变2019","authors":"Chutima Kunacheewa, Pei Lin, Elisabet E. Manasanch","doi":"10.1002/acg2.71","DOIUrl":null,"url":null,"abstract":"<p>New treatments for multiple myeloma have emerged with excellent outcomes. Minimal residual disease monitoring, one of the most important parameters that can predict long term survival, has also been developed over time. Bone marrow assessment by either muti-color flow cytometry or next generation sequencing, as well as whole body imaging are response endpoints required by the IMWG 2016. Other approaches such as liquid biopsies – using cell free DNA, circulating tumor cells or mass spectrometry- are under investigation and may have future clinical applications in myeloma.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.71","citationCount":"3","resultStr":"{\"title\":\"Minimal residual disease in multiple myeloma 2019\",\"authors\":\"Chutima Kunacheewa, Pei Lin, Elisabet E. Manasanch\",\"doi\":\"10.1002/acg2.71\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>New treatments for multiple myeloma have emerged with excellent outcomes. Minimal residual disease monitoring, one of the most important parameters that can predict long term survival, has also been developed over time. Bone marrow assessment by either muti-color flow cytometry or next generation sequencing, as well as whole body imaging are response endpoints required by the IMWG 2016. Other approaches such as liquid biopsies – using cell free DNA, circulating tumor cells or mass spectrometry- are under investigation and may have future clinical applications in myeloma.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.71\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.71\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New treatments for multiple myeloma have emerged with excellent outcomes. Minimal residual disease monitoring, one of the most important parameters that can predict long term survival, has also been developed over time. Bone marrow assessment by either muti-color flow cytometry or next generation sequencing, as well as whole body imaging are response endpoints required by the IMWG 2016. Other approaches such as liquid biopsies – using cell free DNA, circulating tumor cells or mass spectrometry- are under investigation and may have future clinical applications in myeloma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
